WO2001036656A2 - A complex between hyaluronic acid and a biomolecule and its use - Google Patents
A complex between hyaluronic acid and a biomolecule and its use Download PDFInfo
- Publication number
- WO2001036656A2 WO2001036656A2 PCT/SE2000/002245 SE0002245W WO0136656A2 WO 2001036656 A2 WO2001036656 A2 WO 2001036656A2 SE 0002245 W SE0002245 W SE 0002245W WO 0136656 A2 WO0136656 A2 WO 0136656A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- complex
- kda
- biomolecule
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the present invention relates to a new biomolecular complex formed by hydrophobic interactions, a method for the preparation of the complex and the use of said complex for the manufacture of pharmacologically active compositions.
- the present invention further makes available novel methods of treatment, based on the administration of compositions comprising the new biomolecular complex.
- Proteins and peptides are proteins and peptides, such as insulin, hormones etc.
- the ongoing developments in protein chemistry makes it highly probable that numerous therapeutically effective proteins or peptides are still to be discovered or synthesised. Proteins and peptides are however digested in the gastrointestinal tract, and thus unsuitable for oral administration. Therefor protein and peptide drugs are presently administered parenterally, e.g. by subcutaneous injection.
- Hyaluronic acid is a naturally occurring glycosaminoglycan consisting of a linear polymer of repeating units of glucuronic acid and N-acetyl-glucosamine. The molecular weight can vary over a wide range depending on the source.
- Hyaluronic acid is present in several tissues of animals, and in some specific organs, such as rooster combs, in concentrations high enough for commercial scale extraction. Such tissues contains hyaluronic acid of a wide range of molecular weights and are purified during a complex series of extraction, purification and sterilisation steps. This results in a final product having a high molecular weight within a considerably more narrow molecular weight range.
- Hyaluronic acid is non-toxic, readily decomposed in the body, and thus suitable for pharmacological use.
- HEALON ® Kabi Pharmacia AB, Uppsala, Sweden
- HEALON ® Kabi Pharmacia AB, Uppsala, Sweden
- hyaluronic acid is mentioned as a slow release carrier in a subcutaneously injected slow release depot, together with a binding protein for e.g. GH or IGF.
- the active substances are linked to the hyaluronic acid by covalent bonds.
- Hyaluronic acid has also been used to improve the adhesion of biomolecules to biologic membranes and thus improve the internalisation of biomolecules.
- the main medical use of hyaluronic acid is presently the administration of purified hyaluronic acid (of animal origin or synthetized by use of recombinant cells) directly at sites, where either a mechanical functional barrier is required (viscosurgery, viscoprotection, viscoseparation, e.g. in ophthalmic surgery) or where mechanically dysfunctional tissue can be supplemented (viscosupplementation, viscoaugmentation, e.g. in cosmetic surgery).
- Chitosan a cationic polymer, has been shown to function as a delivery vector for DNA.
- a particulate complex of chitosan and nucleic acid is suggested to function as a novel, non-viral vector for gene-therapy.
- the chitosan is explained to compact the plasmid DNA into a nanoparticle of between 10 nm and 1 ⁇ m and confer upon the compacted material suitable surface characteristics that lead to good adherence of the particle to the surface of the target cell, followed by internalization and expression of the encoded material.
- This complex is suggested to enchance the expression of nucleic acids in epithelial tissues, such as the GI- tract, the vagina, the rectum, the nasal cavity, the lungs and the buccal cavity.
- WO98/01160 is limited to chitosan, a polyglucosamine extracted from marine evertebrates or the exoscelet of insects. Chitosan is thus a substance foreign to the human body, and it cannot be metabolized by the human body, with exception for the possibility of bacterial degradation possibly taking place in the colon.
- hyaluronic acid is suggested for use as a DNA carrier for gene therapy to treat abnormal retinal vasciularization.
- the nucleic acid is not compressed and the hyaluronic acid is used merely as a targeting agent, relying on its ability to bind to cell membranes.
- a mixture of insulin and DEAE-dextran or chitosan is delivered to the mucosal surface of a human, e.g. to the mucosal surface of the vagina, the eye, colon or nasal cavity.
- One objective of the present invention is to make available biomolecules capable of efficient uptake in the body of a mammal, and in particular after oral administration, and exhibiting therapeutic effect after oral administration.
- Another objective of the present invention is to make available a biomolecule capable of passing the brain-blood-barrier.
- Another objective of the present invention is to make available a new vector for gene therapy, avoiding the potentially harmful immunologic response ellicited by viral vectors. Another objective is to make available a hormone formulation for oral administration, said formulation exhibiting therapeutic effect in vivo after oral administration.
- Still another objective is to make available an insulin formulation for oral administration, said formulation exhibiting therapeutic effect in vivo after oral administration.
- Still another objective is to make available a growth hormone formulation for oral administration, said formulation exhibiting therapeutic effect in vivo after oral administration.
- Still another objective is to make available a heparin formulation for oral administration, said formulation exhibiting therapeutic effect in vivo after oral administration.
- a further objective of the present invention is to make available a method of delivering therapeutically active biomolecules orally, obliterating the need for parenteral administration, e.g. injections.
- An objective of the invention is to make available novel methods of treatment, wherein a therapeutically active biomolecule is delivered orally.
- the present invention solves the above problems by making available a new complex between a pharmacologically active biomolecule and hyaluronic acid involving hydrophobic interaction according to the attached claims, incorporated herein.
- the present invention also makes available novel therapeutic formulations and methods of treatment according to the attached claims.
- peptides are reversibly compressed, e.g. from a size of about 2.4 nm to less than about 0.3 nm, thus improving their ability to penetrate across biological membranes e.g. the gut wall.
- a plasmid-DNA construct has been reversibly compressed from about 87 nm to less than about 10 nm, improving the DNA-structure for free passage through the nuclear pore.
- inventive complexes with growth hormone, insulin and heparin have been produced and tested.
- One way of producing these new hydrophobic complexes is by pH-changes, by elimination of molecular charge and bonds, by evacuation of water and ions, and finally stabilisation with hyaluronan.
- These reversibly compressed complexes can be administrated by new routes and thereby avoid the need of parental administration.
- the new routes made available for these complexes include oral, pulmonary, nasal, and topical administration, and intra cellular trafficking.
- Avoiding parenteral administration will make drug application more convenient, e.g. for out patients, self-medicating patients, and especially for children and the elderly.
- a drug according to the invention will also be easier to handle, which will result in an improved compliance.
- Fig. 1 shows the hydrodynamic radius in nm as a function of hyaluronic acid concentration in ug/ml in different dilutions
- Fig. 2 shows the kinetic blood glucose profile in six rats, receiving an insulin-Hy complex (2.44 mg/ml, 9.5 U) by subcutaneous injection;
- Fig. 3 shows the kinetic blood glucose profile in six rats, receiving an insulin reference (4.56 mg/ml, 17.8 U) by subcutaneous injection;
- Fig. 4 is an AFM (Atomic Force Microscopy) photography of a sample of the insulin-Hy complex at a concentration of 134 U insulin / ml, showing clearly visible dots;
- Fig. 5 is an AFM photography of a sample of the insulin-Hy complex at a concentration of 40.4 U insulin / ml, showing clearly visible dots;
- Fig. 6 shows the blood glucose levels in three rats, after oral administration of an insulin-Hy complex (1 ml, 28 U/ml);
- Fig. 7 shows the blood glucose levels in three rats, after oral administration of an insulin-Hy complex, where rat no. 1 and no. 2 were on starvation diet, and rat no. 1 received 0.2 ml 134 U/ml or 27 U, rat no. 2, 1 ml 62 U and rat no. 3 was on normal diet and received 1 ml, 62 U insulin;
- Fig. 8 shows the blood glucose levels in two rats, after subcutaneous administration of the insulin reference (0.065 ml, 4 mg/ml, 6.8 U);
- Fig. 9 shows the weight increase in % in Hx rats receiving the rhGH complex, compared to non-treated rhGH and placebo.
- the present invention concerns a method for forming a complex between hyaluronic acid and a biomolecule involving hydrophobic interactions, the oral administration of these biomolecules, and various methods involving the administration of these biomolecules.
- the biomolecule is rendered at least partially hydrophobic by a process herein called compression.
- the invention thus makes available a method for the manufacture of compressed biomolecules and complexes according to the invention.
- biomolecule is used in the description, examples and claims to define all molecules, synthetic and natural, exhibiting an effect in vivo.
- biomolecules include peptides, proteins, glycoproteins, glucosaminoglucans, and sugars.
- pharmaceutically active substance is used as a synonym to the above.
- peptide includes hormones, neuropeptides, signal peptides, peptide antibiotics, peptide antigens and other naturally occurring or synthetic amino acid polymers.
- hormones such as insulin, growth hormone, human growth hormone, glucagon, corticotropin, oxytocin, bradykinin, thyrotropin-release factor and thyrotropin, enkephalins, and peptide antibiotics.
- proteins includes enzymes, transport proteins, nutrient and storage proteins, contractile or motile proteins, structural proteins, defence proteins, regulatory proteins and other proteins, according to a text book definition.
- recombinant and synthetic proteins suitable for use according to the present invention are enzymes, such as oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases; transport proteins such as metalloproteins, hemoproteins, phosphoproteins, glycoproteins and lipoproteins; defense proteins, such as proteins taking part in the immune defense, e.g. immunoglobulins, antibodies, proteins taking part in tissue repair, e.g. fibrinogen, thrombin etc; regulatory proteins, such as hormones, growth factors, e.g.
- EGF epidermal growth factor
- NGF nerve growth factor
- FGF fibroblast growth factor
- PDGF platelet derived growth factor
- ILL IL-2 interleukins
- hydrophobic binding is used in this context to define bindings that are essentially of hydrophobic nature and influenced by long range forces, such as van der Waals forces between hydrophobic parts of a biomolecule and the hydrophobic parts of a molecule surrounding the biomolecule.
- compression and “compressed” as in “compressed biomolecule” are used in this text to define a reversible size reduction, performed on the biomolecules according to the inventive method.
- reversible in this context means that the biomolecule retains or regains its biologic effect in vivo after compression and administration to a mammal, in particular after oral administration to a mammal.
- hyaluronic acid is meant hyaluronic acid both in protonated and non-protonated form, irrespective of origin.
- the invention thus encompasses the use of hyaluronic acid of both animal and bacterial origin, for example hyaluronic acid produced by genetically modified organisms.
- the invention encompasses the use of all hyaluronic acid derivatives, which do not compromise the physiological properties associated with hyaluronic acid.
- the invention encompasses the use of derivatives and complexes which can be converted to hyaluronic acid in the human gastrointestinal tract.
- hylauronic acid molecules exist normally in the form of loops, but the present inventor has surprisingly found that it can be straightened in the presence of protons, H+.
- H+ protons
- Hy hyaluronan
- Hy hyaluronan
- plasmid preferabbly less than about 10 nm
- peptides preferably less than about 0.3 nm
- ions are cationic ions: NH + , K + , Na + and anionic ions: sulfates, chloride, carbonates, acetates.
- a stable complex/polymer is formed by Hy surrounding the plasmid, the peptides respectively when Hy changes its structure back to a curled structure when pH is changed to pH 6. It is then possible to dilute the solutions to the desired strength.
- the resulting polymer complex can be produced in the form of a precipitate, a colloidal solution or a true solution, preferably in the form of a colloidal solution.
- the complex can also be prepared in the form of a lyophilised powder.
- Another embodiment of the present invention is a method for the production of the hydrophobic biomolecular complex.
- the method includes the steps of:
- step a) dialysing the biomolecular structure, thereby obtaining a compressed hydrophobic complex with the polar groups buried and the polymer surrounding the biostructure.
- the acid in step a) is hydrochloric acid, sulphuric acid, phosphoric acid or acetic acid, and the pH is less than 3, preferable in the range of 1.0 to 2.5.
- the electrolyte of step b) contains cations such as NH 4 + , K + , Na + , Ca “"”” , Mg “+ , Zn 2 ", Fe 2+ , Fe 3+ and anions such as sulfates, chloride, and acetates.
- the hydrophobic biomolecular complex is used as a medicament.
- hyaluronic acid can be used in the manner described in the present description and examples, as one problem encountered with hyaluronic acid is its extreme and undesired adsorption of peptides. This is a well documented problem in the production of hyaluronic acid for medical purposes, where peptide contamination or oligonucleotide contamination (e.g. DNA, RNA) renders the product impossible to use, as the remaining peptides are pyrogenic or irritating for the patient.
- peptide contamination or oligonucleotide contamination e.g. DNA, RNA
- a problem specific for the administration of insulin is the very narrow dose interval tolerated by the patients. It is therefor highly surprising that the complex of hyaluronic acid and insulin according to the present invention both gives effect at low doses and is well tolerated also at very high doses, as shown in the in vivo experiments.
- inventive complexes of biomolecules and hyaluronic acid are also suitable for parenteral administration. In this application they have the advantages of sustained effect and higher dose tolerance. Further, the need of chemically modifying the substances - other than forming the complex with hyaluronic acid — is avoided.
- a complex according to the invention is administered to the patient orally, in the form of a suspension, a capsule, a tablet, an enteric coated capsule or another oral delivery form, including vehicles and adjuvants commonly used for oral preparations.
- a complex according to the invention is administered to the patient transdermally, in the form of a suspension, a gel or paste, or another oral delivery form, including vehicles and adjuvants commonly used for transdermal preparations.
- a complex according to the invention is administered to the patient nasally, in the form of an aerosole of liquid or solid particles, or another nasal delivery form, including vehicles and adjuvants commonly used for nasal preparations.
- the inventive complex can be administered orally, by inhalation, in the form of an aerosole of liquid or solid particles, or another delivery form, including vehicles and adjuvants commonly used for preparations intended for inhalation.
- inventive complex is specially suited for oral delivery, it may also be subcutaneously or intramuscularely administered. When administered parenterally, the inventive complex will exhibit better bioavailability, and it may function as a sustained release preparation.
- hyaluronic acid has a special advantage in that endogenous pathways are readily available to metabolize the hyalyuronic acid. Further, as the human body has a high capacity to metabolize large quantities of hyaluronic acid, the small quantities applied therapeutically according to the present invention do not add significantly to the systemic metabolic burden.
- inventive complex and methods also have an considerable advantage in that presently available pharmaceuticals, approved for human use, can be used more efficiently and - in the case of oral administration - delivered via a novel route of administration, hitherto unavailable for these pharmaceuticals.
- hyaluronic acid and the pharmaceuticals suggested for use according to the present invention are thoroughly investigated, the tests required for the new complexes can be minimised.
- An advantage of the present invention is further, that the cost of production for most of these novel drugs will be less than the cost for parenteral drugs, since there are less strict requirements for sterile production of drugs administered orally.
- Example 1 The influence of pH-change on hydrodynamic radius
- Hy The particle size of Hy was studied upon pH-changes. Dynamic light scattering, 500 mV, was determined for three concentrations of Hy 90, 30 and lO ⁇ g/ml. Malvern, ZetaMaster S, version PCS: v 1.26 was also used to determine pH and ⁇ -potential
- the resulting relaxation time distributions are essentially single-modal under all conditions.
- the peak width decreases systematically with increasing concentration due to a greater signal to noise ratio.
- Figure 1 shows the hydrodynamic radius (Rn) in nm (0 - 300) as a function of concentration of Hy in ⁇ g/ml.
- the calculated hydrodynamic radii fall on the same line for the undiluted samples and those diluted with water.
- Those samples diluted with acid have considerably larger particle size.
- the true particle sizes in contrast to the apparent values which are influenced by interactions at finite concentrations are 65 nm (water solutions) and 105 (acid diluted).
- the scattered intensities are the same for the undiluted and water diluted samples, but about the double in value for the acid-diluted. For example, 11 kHz for the water-diluted and 26 kHz for the acid-diluted solutions. This is consistent with an increase in particle dimensions in acid-diluted solutions of Hy. This is indicative for that the Hy structure upon strong acid addition is stretching out from a curling cylinder to straight line.
- Hy with a molecular weight of 150 k Dalton becomes positively charged (3.1-16.9 mV) when pH changes from pH 6.5 to 1.5.
- Particle size measurements by dynamic light scattering 500 mV indicate that the Hy structure is stretched out from a curled cylinder to a straight line upon addition of a strong acid. pH is changed from 6.5 to 1.5 and the hydrodynamic radii is almost doubled or changed from 65 to 105 nm.
- Example 2 Preparation of a complex of insulin and hyaluronan for oral and parenteral administration
- the aim of this study was to evaluate if the insulin complex had biological effect, the duration of such an effect and the dose required to obtain a significant decrease in blood glucose level.
- Hy Hyaluronan
- a placebo solution consisting of an aqueous isotonic sodium chloride solution (0.9%)
- the preparations were made under sterile conditions.
- Aqua Sterilisata (Kabi Pharmacia AB Sweden); human albumin solution, 200 mg/ml (Pharmacia & Upjohn); isotonic sodium chloride solution (0.9% 1, pH 6.0, Kabi Pharmacia AB Sweden); 1 M sodium sulfate; 1 M and 6 M hydrochloride acid; 5 M sodium hydroxide; isotonic Tris buffer (10 mM pH 6.5, sodium chloride 0.9%), and hypotonic Tris buffer (10 mM pH 6.5).
- a defined amount of insulin (45 mg) was dispensed into a sterilized glass bottle.
- Hy (92 mg) was slowly dissolved in sodium sulfate (6.5 ml, 1 M) in a sterile glass container. The mixing was interrupted when the solution became transparent. 1 M hydrochloride acid was then added to the mixture of Hy to pH 1.51 - 1.58. The insulin (45 mg) was then added to the Hy- solution and dissolved. The mixture (pH 1.5) was gently dispersed and transferred into dialysis bags.
- a defined amount of insulin (45 mg) was dispensed into a sterilized glass bottle.
- Hy (78.9 mg) was slowly dissolved in sodium sulfate (7.0 ml, 1 M) in a sterile glass container. The mixture was allowed to become transparent. 1 M hydrochloride acid was added to reach pH 1.6. Insulin (45.1 mg) was then added to the Hy solution together with hydrochloric acid (0.2 ml, 1 M)and sodium sulfate (0.8 ml, 1 M) to properly dissolve the insulin (pH 1.80). The mixture was transferred into dialysis bags.
- Insulin 40mg was dissolved in an isotonic sodium chloride solution (8.0 ml) in a sterilized glass bottle. The pH was adjusted to 1.8. The resulting transparent solution was dispensed into dialysis bags.
- dialysis bags (Spectra Pore R MWCO 6-8000) each with a volume of 4 ml were prepared.
- the three preparations (3x2) were placed in a beaker containing a buffer solution.
- the dialysis procedure was performed according to Table 1 below.
- Buffer solutions an isotonic Tris buffer (10 mM, pH 6.5, 0.9% NaCl) in the following designated “isotonic”, and a hypotonic Tris buffer (10 mM, pH 6.5), in the following designated “hypotonic” were respectively used to dialyse the preparations. _. .
- the dialysis medium was changed after different time intervals.
- the pH of the medium outside the dialysis bags was measured after each dialysis period and the preparations were inspected. The pH did not exceed pH 6.5 at any point.
- the content of the dialysis bags were pooled for each preparation and transferred into sterile glass bottles which were closed and placed at + 4°C. These solutions were refereed to as "stock solutions" of the final insulin-Hy complexes according to the invention, and the "insulin reference".
- the first stock solution "Preparation I” had a volume 9.5 ml and pH 6.4, and appeared as a transparent solution/gel with some cloudiness/precipitate. Amino acid analysis was performed, and indicated a concentration of 5.16 mg/ml insulin or 134 U /ml. Preparation I was used for i) Atomic Force Microscopy (AFM), and ii) oral administration to rats (dose 0,2 ml, 27 U). The second stock solution "Preparation II” had a volume of 15.5 ml and pH 6.4, and appeared as a transparent solution with some cloudiness/precipitate. Amino acid analysis was performed, and indicated a concentration of 2.44 mg/ml insulin or 63 U /ml. Preparation II was used for i) subcutaneous injections in rats, and ii) kinetic studies in six rats, subcutaneous injection.
- the third stock solution "Preparation III” had a volume of 8.2 ml, and pH 6.4, and appreared as a transparent solution. Amino acid analysis was performed, and indicated a concentration of 4.57mg/ml insulin or 1 18.9 U /ml. Preparation III was used as the insulin reference solution.
- composition of the insulin-Hy complex was:
- the blood glucose levels were followed for 9 hours.
- the blood glucose values were for Ultratard 7.58 mMol/1, for the insulin reference solution 8.52 mMol/1, for the insulin-Hy complex 9.78 mMol/ml, and for placebo 20.36 mMol ml. , r
- the kinetic behaviour was studied for the insulin-Hy complex 2.44 mg /ml, given 0.05 ml x 3, and for the insulin reference solution 4.56 mg/ml given 0.05 ml x 3.
- the blood glucose levels were followed after subcutaneous injections. See Figure 1 and 2.
- the objectives of these studies were to determine the dose level and concentration of the insulin-Hy complex in streptozotocin diabetic rats by finding a measurable absorption of orally administered insulin in form of the inventive insulin-Hy complex.
- the blood glucose level was observed in order to detect a possible effect of the complex.
- the Sprague Dawley rats were fed 1ml of the samples by a tube in the stomach.
- Insulin-Hv complex 0.4, 3.2 and 28 U / ml.
- Oral dose given 1 ml - 0.4, 3.2, 28 U respectively.
- Reference insulin solution for subcutaneous injection, recombinant human insulin 3.86 mg / ml or 33.4 U / ml.
- Subcutaneous dose given 65 ⁇ l - 6.5 U
- the insulin-Hy complexes were prepared essentially as described above (Example 2) and aseptically transferred into injection vials. Human albumin 0.27%) was omitted in the oral preparations.
- the mixtures were contained in the vials at 8 °C prior to oral administration.
- the stability of the solutions at 8 °C was found to be at least 2 months (no physical or biological changes of the preparations were observed).
- the insulin-Hy complex 0.4, 3.2 and 28 U/ml were given orally to streptozotocin diabetic rats (streptozotocin i. v.; 40 mg/kg bodyweight).
- Insulin reference (4.56mg/ml, 0.05ml x 3): 17.8 U resulted in a decrease in blood glucose level from 20.3 mMol/1 to 8.5 mMol/1 for more than eight hours.
- Insulin-Hv complex (2.44 mg / ml 0.05x3): 9.5 U resulted in a decrease in blood glucose level from 20.3 mMol/1 to 9.7 mMol/1 for more than eight hours.
- Rats were starved during one night, but supplied with water. On the morning the blood glucose level was determined. Three rats were studied for oral absorption. Two of them were on starvation diet and orally treated with 26.8 U, 62 U respectively. One of them, not on diet, was orally treated with 62 U. Two reference rats were given subcutaneous injections. All rats responded with a decrease of the blood glucose level, as seen in Figures 7, and 8.
- the differences between the results may be explained by the activity pattern of the rats, considering the fact that the insulin-Hy complex was orally administered in the morning to rats with a stomach filled with food.
- Heparin (16.1 mg) having a molecular weight of 7.500 Dalton (Sigma) was dispensed in a sterilized glass bottle.
- Hyaluronan (30.0 mg) was slowly dissolved in sodium sulphate (1,2 ml, 1 M) in a sterilized glass container, and stirred until transparent.
- Hydrochloride acid (0.85 ml, 1 M) was added to pH 1.48. The heparin was then added to the hyaluronan solution and dissolved. The mixture was transferred into dialysis bags.
- Buffer solution A hypotonic Tris buffer (10 mM, pH 7.5) designated “hypotonic”, was used to dialyse the preparations.
- the dialysis medium was changed after different time intervals.
- the pH of the medium outside the dilysis bags was measured after each dialysis period and the preparations were inspected. The pH did not exceed pH 6.5 at any point.
- the content of the dialysis bags were pooled, and transferred into a sterile glass bottle which were closed and stored at 4°C.
- the dialysed heparin-Hy complex had a volume of 1.05 ml, and pH 7.2, and appeared as a transparent solution.
- the preparation was used for particle sizing in a Malvern ZetaSO apparatus, version PCS vl.29.1. The size by volume was determined to be 1272 nm for this preparation.
- This example illustrates the mechanisms of Hy in obtaining a durable compact plasmid-DNA- structure.
- the gene expression of the plasmid is encoded for Chloramphenicol Acetyl Transferace, CAT.
- Solution 1 Plasmid pRc/CMV-CAT, double strained closed-ring structure -6400 base pair. molecular weight 4 250 000 Dalton 200 ⁇ L was used in the concentration of 130 ⁇ g/ml.
- Solution 2 10.4 mg Hy molecular weight 150 000 Dalton was dissolved in 100 ml water in a concentration of 104 ⁇ g/ml.
- 250 ⁇ L is diluted to 500 ⁇ L by pH shift pH 7.4/ 2.4 and precipitated by NaCl 2M.
- Dialyse-tube, Spectra Pore Membrane MWCO 6-9,000 Record No 132645 was used.
- the tube was softened in distilled water for lh.
- the tube was then cut and a dialyse-clamp was fitted at one edge of the tube.
- 500 ⁇ l was filled in the bag.
- the filling was done with a sterile micro-pipette.
- the other edge of the tube was fitted with a dialyse-clamp, and the resulting bag was dialysed for 30 h. Then the integrity of the membrane was controlled.
- the dialysed solution was aspirated with a sterile micro-pipette and the volume determined ( ⁇ l).
- Hy present in strong acid-solutions should be avoided due to a breakdown of the Hy structure and to a loss of the acetyl group.
- the time to form a complex between Hy and different plasmid in strong acid solution should therefore be limited to around 30 min.
- Hy solution pH 1.75
- the samples were dialysed within 30 min against 0.15 M NaCl to rise the pH.
- Hy-plasmid complex was formulated to contain (510 ⁇ l): pRc/CMV-CAT 26 ⁇ g / 50.98 ⁇ g/ml / 12.0 nM
- Solution 1 plasmid pRc/CMV in 0.15 M NaCl (1+1) 130/2 ⁇ g/ml 30.57/2pM).
- Solution 2 Hya 150 000 Dalton 104 ⁇ g/ml (69.3pM) in distilled water.
- the plasmid pRc/CMV-CAT has been compressed from 87.1 nm to 7.5 nm.
- the methods involve acidification, forming a complex, salting and dialyse treatment, at a molar ratio of plasmid/Hy 150 000 Dalton 0.83-0.85:1.
- Dynamic light scattering identifies the diameter of the complex pRc/CMV-CAT- Hy (7.5nm).
- Hy- structure Hy PH 8. 8 ⁇ -potential -51 to -69mV ⁇ Hy pH 1.75 1.6 ⁇ 2.3mV
- pH-shift pH-shift
- an ionic concentration change of NaCl 2 M to 0.075 M forms the complex.
- a plasmid-Hy complex was prepared for use in transfection studies in cells, and for physicochemical characterisation after three (3) months of storage.
- the preparation was done with a newly prepared plasmid (cone. 0.67 ⁇ g/ml) with the following changes; a new molar ratio plasmid Hy 0.1 128 (molar ratio plasmid / Hy 0.085), batch size 1020 ⁇ l (520 ⁇ l), pH 1.65 and 1.8 (pH 1.75 and 1.08).
- the complex formation is based on a positive charging of the Hyaluronan (Hy) structure (Hyoest. w ⁇ -61.5 ⁇ 8.5mW Hy ⁇ pH 1.55 -2.4 + 2.2mV, Hy es t. w ⁇ -61.5 ⁇ 8.5m VI Hy ⁇ pH ⁇ .so - 4.0m V ⁇ 1.9 V)
- the Plasmid-Hy complex is determined after 3 months of storage at 5-8°C and characterised by a plasmid compression of the plasmid from 356 (98.9 -507) nm at pH-shift 1.65 > 6.0 to 84.41 nm at pH-shift 1.80 > 6.0 to 69.0 nm identified by dynamic light scattering (see Table 7).
- Plasmid-complex Naked plasmid H Hyy 110044 ⁇ gg//mml
- This example illustrates the compression of rhGH.
- Hy By changing pH to a strong acid-solution (pH 1.5) Hy becomes charged stretching out from a curled cylinder to a straight line. At this pH, rhGH is easily soluble. The size of the rhGH particles is moderated by the speed of the pH-change and the ionic concentration change from 2 M to 0.15 M NaCl.
- the pH-interval used is 7 - 1.5 - 5.0 (pi) at a constant ratio of rhGH: Hy.
- Hy stabilises the dispersion in changing its structure back to curled structure at about pH 6 to 7.
- the preparations were assayed with HI-HPLC.
- the particle size of the compressed and the None compressed rhGH was determined by light scattering, Z-master, after storage at 5 - 8°C for 30 days.
- the diameter of the measured particles is given in means of six measurements.
- Hy 20.78 mg Hy with a molar mass of 150 KDa was dissolved in 900 ⁇ l distilled water and was allowed to react for more than 1 hour.
- the pH 9.2 of the Hy-solution was adjusted to pH 1.51 with 50 ⁇ l water and 50 ⁇ l 1 M HCl.
- the tubes were dialysed in Tris buffer 10 mM pH 7.9. The solution, volume 600 ml, was exchanged 3 times. See Table 8.
- the above-prepared compressed rhGH and non-compressed rhGH were used for analytical assay (in situ determined biological activity and for particle sizing.
- concentrations used for particle sizing of compressed rhGH was 7.6 mg/ml and 9.3 mg/ml and for non-compressed rhGH 15 mg/ml.
- the measurements, means of six measurements were done at 25°C.
- HI-HPLC assay is commonly used to determine biological activity of rhGH
- Example 10 Biological activity of rhGH-Hy complex and non-treated rhGH
- Hy 14.9 mg Hy with a molar mass of 150 KDa was dissolved in 1200 ⁇ l 1 M Na?S0 and was allowed to react for more than 1 hour
- the pH of the Hy-solution pH 7.6 was adjusted to pH 1.51 with 100 ⁇ l water and 330 ⁇ l HCl 1 M to a clear solution. HCl was added slowly, and when passing pH 3.8 a precipitate was observed.
- the tubes were dialysed in T ⁇ s buffer 10-mM pH 7.9. The solution, volume 600-ml, was exchanged 3 times. See Table 11.
- Dialyse time pH m Dialyse pH Ocular/ pH Ocular/ pH Ocular/ PH Ocular/ in hour Solution volume volume in volume volume 620 620 620 620 620
- the above-prepared compressed rhGH and non-compressed rhGH are used for analytical assay (in situ determined biological activity), in vivo biological activity and for particle sizing.
- concentrations used for particle sizing compressed rhGH were 5,3 mg and 1.5 mg and for non-compressed rhGH 5-10 mg.
- the sizing is given in means often measurements and was done at 18, 25 and 30°C.
- HI-HPLC analysis of compressed and of non-compressed rhGH was performed.
- HI-HPLC assay is commonly used to determine the biological activity of rhGH. Table 12. Analysis of rhGH
- the radius of compressed rhGH is smaller than non-compressed rhGH. That is, at a concentration of 5.3 mg/ml one compressed unit of rhGH is estimated to have a hydrodynamic radii of 0.22- 0.29 nm and at 1.5 mg/ml 0.70-0.77 nm. At a concentration of 14.5 mg ml non-compressed rhGH is estimated to have a hydrodynamic radii of 2.4 nm.
- the dose response of 0.04 IU/ml and 0.16 IU/ml of compressed rhGH and of non-compressed rhGH were evaluated in groups of 10 Hx rats.
- a group was treated with a placebo solution (Bovine albumin 12.5 ml (200 mg/ml) was diluted with isotonic NaCl to 1000 ml. This solution, containing 1.25% albumin, was used as placebo and to dilute the solutions of compressed rhGH and non-compressed rhGH to doses for animal trials.)
- Injection solutions of compressed and of non-compressed rhGH were prepared by dilution with Diluent 1.25 % Albumin solution to desired strength, low dose 0.04 IU/ml and high dose 0.16 IU/ml. Diluent 1.25 % Albumin solution was used as placebo.
- Figure 9 illustrates the weight gained inc of administered dose (treatment of rhGH in i.u./kg body weight for different doses). Dose response of compressed and non-compressed rhGH in % weight gain is demonstrated Table 14 after subcutaneous injection in Hx rats.
- a dose response in % weight gain is demonstrated for compressed, and for non-compressed rhGH in Figure 9 and Table 14.
- compressed rhGH an 8 % weight gain was registered for the 0.32 IU/kg dose, and a 10 % weight gain for the 1.22 IU/kg dose.
- non-compressed rhGH an 8 % weight gain for 0.32 IU/kg, and 12 % for 1.24 IU/kg was registered.
- Placebo no weight gain was obtained.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002391647A CA2391647C (en) | 1999-11-15 | 2000-11-15 | Biomolecular complex formed between hyaluronic acid and a biomolecule |
EP00980185A EP1231926B1 (en) | 1999-11-15 | 2000-11-15 | Biomolecular complex formed between hyaluronic acid and a biomolecule, its method of manufacture and medical uses thereof |
AU17481/01A AU1748101A (en) | 1999-11-15 | 2000-11-15 | New complex, and methods for its production and use |
AT00980185T ATE287720T1 (en) | 1999-11-15 | 2000-11-15 | BIOMOLECULAR COMPLEX FORMED FROM HYALURONIC ACID AND A BIOMOLECULE, PRODUCTION PROCESS THEREOF AND THEIR THERAPEUTIC USE |
DK00980185T DK1231926T3 (en) | 2000-11-15 | 2000-11-15 | Biomolecular complex formed by hyaluronic acid and a biomolecule, a process for its preparation and medical use thereof |
DE60017783T DE60017783T2 (en) | 1999-11-15 | 2000-11-15 | BIOMOLECULAR COMPLEX MADE FROM HYALURONIC ACID AND A BIOMOLECULAR, METHOD OF MANUFACTURING THEREOF AND THEIR THERAPEUTIC USE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904121A SE9904121D0 (en) | 1999-11-15 | 1999-11-15 | Hydrophobic biomolecular structure |
SE9904121-2 | 1999-11-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001036656A2 true WO2001036656A2 (en) | 2001-05-25 |
WO2001036656A3 WO2001036656A3 (en) | 2001-11-15 |
WO2001036656B1 WO2001036656B1 (en) | 2002-02-28 |
Family
ID=20417718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2000/002245 WO2001036656A2 (en) | 1999-11-15 | 2000-11-15 | A complex between hyaluronic acid and a biomolecule and its use |
Country Status (9)
Country | Link |
---|---|
US (3) | US6448093B1 (en) |
EP (1) | EP1231926B1 (en) |
AT (1) | ATE287720T1 (en) |
AU (1) | AU1748101A (en) |
CA (1) | CA2391647C (en) |
DE (1) | DE60017783T2 (en) |
ES (1) | ES2236004T3 (en) |
SE (1) | SE9904121D0 (en) |
WO (1) | WO2001036656A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1480656A1 (en) * | 2002-02-15 | 2004-12-01 | Research Development Foundation | Hyaluronic acid mediated adenoviral transduction |
EP1625851A1 (en) * | 2003-05-16 | 2006-02-15 | BBK Bio Corporation | Preparation for preventing contact of pathogenic matter with living organism |
WO2007028196A1 (en) * | 2005-09-07 | 2007-03-15 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
US7338931B2 (en) * | 1999-11-15 | 2008-03-04 | Gustaf Jederstrom | Hydrophobic biomolecular structure |
WO2008136759A1 (en) * | 2007-05-07 | 2008-11-13 | Jederstrom Pharmaceuticals Ab | Stabilized suspension |
FR2925333A1 (en) * | 2007-12-19 | 2009-06-26 | Farid Bennis | PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES |
US8287894B2 (en) | 2000-07-14 | 2012-10-16 | Alchemia Oncology Pty Limited | Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
US8741970B2 (en) | 1999-01-13 | 2014-06-03 | Alchemia Oncology Pty Limited | Composition and method for the enhancement of the efficacy of drugs |
US8937052B2 (en) | 2005-07-27 | 2015-01-20 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2014120626A (en) * | 2014-05-22 | 2015-11-27 | Владимир Андреевич Сабецкий | INSULIN-CONTAINING MEDICINE OF LONG-TERM ACTION |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014995A2 (en) * | 1979-02-21 | 1980-09-03 | Pharmacia Ab | Immunisation agent, a method of preparing the same and use thereof for producing antisera |
WO1991004058A2 (en) * | 1989-09-21 | 1991-04-04 | Norpharmco Inc. | Treatment of conditions and disease |
WO1997037680A1 (en) * | 1996-04-05 | 1997-10-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
WO1998001160A2 (en) * | 1996-07-10 | 1998-01-15 | Danbiosyst Uk Limited | Compositions suitable for delivery of genes to epithelial cells |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
DE2907070A1 (en) * | 1979-02-23 | 1980-09-04 | Hoechst Ag | HETEROCYCLIC SPIRO-LINKED AMIDINE AND METHOD FOR THE PRODUCTION THEREOF |
LU85582A1 (en) * | 1983-10-11 | 1985-06-04 | Fidia Spa | HYALURONIC ACID FRACTIONS HAVING PHARMACEUTICAL ACTIVITY, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
JPH02213A (en) * | 1987-10-19 | 1990-01-05 | Taiho Yakuhin Kogyo Kk | Long-acting physiologically active peptide preparation |
US5637566A (en) * | 1988-08-24 | 1997-06-10 | Southern Cross Biotech Pty. Ltd. | Method of improving carcass quality by administering growth hormone |
SE8804164A0 (en) | 1988-11-17 | 1990-05-18 | Per Prisell | Pharmaceutical preparation |
JP3283288B2 (en) * | 1991-03-08 | 2002-05-20 | 電気化学工業株式会社 | Bioactive peptide preparation |
ATE173405T1 (en) | 1991-07-10 | 1998-12-15 | Takeda Chemical Industries Ltd | MEDICINAL PRODUCTS BASED ON HYALURONIC ACID |
US5614212A (en) * | 1992-04-08 | 1997-03-25 | International Medical Associates, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US5654006A (en) * | 1993-02-12 | 1997-08-05 | Mayo Foundation For Medical Education And Research | Condensed-phase microparticle composition and method |
WO1995016774A1 (en) * | 1993-12-17 | 1995-06-22 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
ATE212545T1 (en) * | 1995-03-28 | 2002-02-15 | Fidia Advanced Biopolymers Srl | NANOSPHERES WITH A BIOCOMPATIBLE POLYSACCHARIDE |
CN1209068A (en) | 1995-10-23 | 1999-02-24 | 海欧制药澳大利亚有限公司 | Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization |
KR100236771B1 (en) * | 1997-04-01 | 2000-02-01 | 성재갑 | Hyaluronate microparticles for sustained release of drug |
JPH10158196A (en) * | 1996-05-16 | 1998-06-16 | Hisamitsu Pharmaceut Co Inc | Carrier for stabilization of nucleic acid |
SE9904121D0 (en) * | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobic biomolecular structure |
-
1999
- 1999-11-15 SE SE9904121A patent/SE9904121D0/en unknown
- 1999-12-06 US US09/455,472 patent/US6448093B1/en not_active Expired - Fee Related
-
2000
- 2000-11-15 WO PCT/SE2000/002245 patent/WO2001036656A2/en active IP Right Grant
- 2000-11-15 DE DE60017783T patent/DE60017783T2/en not_active Expired - Lifetime
- 2000-11-15 ES ES00980185T patent/ES2236004T3/en not_active Expired - Lifetime
- 2000-11-15 CA CA002391647A patent/CA2391647C/en not_active Expired - Fee Related
- 2000-11-15 AT AT00980185T patent/ATE287720T1/en active
- 2000-11-15 AU AU17481/01A patent/AU1748101A/en not_active Abandoned
- 2000-11-15 EP EP00980185A patent/EP1231926B1/en not_active Expired - Lifetime
-
2002
- 2002-07-02 US US10/186,732 patent/US6926910B2/en not_active Expired - Fee Related
-
2005
- 2005-07-13 US US11/179,673 patent/US7338931B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014995A2 (en) * | 1979-02-21 | 1980-09-03 | Pharmacia Ab | Immunisation agent, a method of preparing the same and use thereof for producing antisera |
WO1991004058A2 (en) * | 1989-09-21 | 1991-04-04 | Norpharmco Inc. | Treatment of conditions and disease |
WO1997037680A1 (en) * | 1996-04-05 | 1997-10-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
WO1998001160A2 (en) * | 1996-07-10 | 1998-01-15 | Danbiosyst Uk Limited | Compositions suitable for delivery of genes to epithelial cells |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Week 9007, Derwent Publications Ltd., London, GB; AN 1990-047916, XP002939890 & JP 2 000 213 A (TAIHOPHARM CO LTD) 05 January 1990 * |
DATABASE WPI Week 9320, Derwent Publications Ltd., London, GB; AN 1993-164366, XP002939889 & JP 5 097 694 A (DENKI KAGAKU KOGYO KK) 20 April 1993 * |
VICTOR A. BLOOMFIELD: 'DNA condensation' CURRENT OPINION IN STRUCTURAL BIOLOGY vol. 1996, no. 6, 1996, pages 334 - 341, XP001009937 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741970B2 (en) | 1999-01-13 | 2014-06-03 | Alchemia Oncology Pty Limited | Composition and method for the enhancement of the efficacy of drugs |
US7338931B2 (en) * | 1999-11-15 | 2008-03-04 | Gustaf Jederstrom | Hydrophobic biomolecular structure |
US8287894B2 (en) | 2000-07-14 | 2012-10-16 | Alchemia Oncology Pty Limited | Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
US8388993B2 (en) | 2000-07-14 | 2013-03-05 | Alchemia Oncology Pty Limited | Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer |
US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
EP1480656A1 (en) * | 2002-02-15 | 2004-12-01 | Research Development Foundation | Hyaluronic acid mediated adenoviral transduction |
EP1480656A4 (en) * | 2002-02-15 | 2007-07-18 | Res Dev Foundation | Hyaluronic acid mediated adenoviral transduction |
US9433637B2 (en) | 2003-05-16 | 2016-09-06 | Kobayashi Pharmaceutical Co., Ltd. | Method for inhibiting influenza virus infection |
US8802641B2 (en) | 2003-05-16 | 2014-08-12 | Natura Corporation | Method for inhibiting onset of or treating pollen allergy |
EP1625851A1 (en) * | 2003-05-16 | 2006-02-15 | BBK Bio Corporation | Preparation for preventing contact of pathogenic matter with living organism |
EP1625851A4 (en) * | 2003-05-16 | 2007-12-26 | Bbk Bio Corp | Preparation for preventing contact of pathogenic matter with living organism |
US8937052B2 (en) | 2005-07-27 | 2015-01-20 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
EP2772260A3 (en) * | 2005-09-07 | 2014-10-15 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
EA013877B1 (en) * | 2005-09-07 | 2010-08-30 | Алкемиа Онколоджи Пти Лимитед | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
US8623354B2 (en) | 2005-09-07 | 2014-01-07 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
WO2007028196A1 (en) * | 2005-09-07 | 2007-03-15 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
EP1922077A1 (en) * | 2005-09-07 | 2008-05-21 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
EP1922077A4 (en) * | 2005-09-07 | 2013-03-06 | Alchemia Oncology Pty Ltd | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
WO2008136759A1 (en) * | 2007-05-07 | 2008-11-13 | Jederstrom Pharmaceuticals Ab | Stabilized suspension |
WO2009083686A1 (en) * | 2007-12-19 | 2009-07-09 | Farid Bennis | Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes |
FR2925333A1 (en) * | 2007-12-19 | 2009-06-26 | Farid Bennis | PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES |
EA023107B1 (en) * | 2007-12-19 | 2016-04-29 | Фарид Беннис | Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes |
Also Published As
Publication number | Publication date |
---|---|
WO2001036656A3 (en) | 2001-11-15 |
CA2391647C (en) | 2008-03-11 |
US20050255162A1 (en) | 2005-11-17 |
ES2236004T3 (en) | 2005-07-16 |
EP1231926B1 (en) | 2005-01-26 |
US6926910B2 (en) | 2005-08-09 |
DE60017783T2 (en) | 2006-01-05 |
US20070275069A9 (en) | 2007-11-29 |
US6448093B1 (en) | 2002-09-10 |
AU1748101A (en) | 2001-05-30 |
WO2001036656B1 (en) | 2002-02-28 |
US20030096266A1 (en) | 2003-05-22 |
CA2391647A1 (en) | 2001-05-25 |
ATE287720T1 (en) | 2005-02-15 |
SE9904121D0 (en) | 1999-11-15 |
EP1231926A2 (en) | 2002-08-21 |
US7338931B2 (en) | 2008-03-04 |
DE60017783D1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Surendrakumar et al. | Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs | |
US9259474B2 (en) | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy | |
US7338931B2 (en) | Hydrophobic biomolecular structure | |
EP2814460B1 (en) | Glucose-responsive microgels for closed loop insulin delivery | |
EP1750679B1 (en) | Gel composition comprising charged polymers | |
EP3566713A1 (en) | Injectable biomaterials | |
WO2007080898A1 (en) | Sustained-release hydrogel preparation | |
US8632803B2 (en) | System for delivery of protein in insoluble fibrillar or aggregate form | |
EP0750515B1 (en) | Low molecular weight hyaluronic acid with peptide or protein | |
KR100939983B1 (en) | Hyaluronic Acid and Hydrophobic Poly Amino Acid Copolymer | |
EP2146750B1 (en) | Stabilized suspension | |
CN116867509A (en) | Injectable biodegradable polymer complexes for glucose responsive insulin delivery | |
EP1500664B1 (en) | Gelatin derivatives and high-molecular micelles comprising the same | |
WO2019118202A1 (en) | Stabilization of glucagon by trehalose glycopolymer nanogels | |
RU2391354C1 (en) | Complex of biologically active recombinant protein with polysialic acid | |
WO2008041704A1 (en) | Controlled release preparation | |
Simon | Insulin nanocomplexes formed by self-assembly from amine-modified poly (vinyl alcohol)-graft-poly (L-Lactide) for non-invasive mucosal delivery: Preparation, characterization and in vivo investigations | |
Simon | zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) | |
KR20070031931A (en) | Gel composition comprising charged polymers | |
AU2002326564A1 (en) | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
B | Later publication of amended claims | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2391647 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000980185 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000980185 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000980185 Country of ref document: EP |